Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dmitry N. Laptev has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Peripheral Immunophenotypes in Association with Autoantibody Positivity, Age of Onset, Progression Stage and Endotypes of Diabetes Mellitus Type 1

    by Alyssa Pekonidi, Nikita Sergeev, Аrtem Fedorinin, Dmitry Laptev, Margarita Samsonova, Maria Terekhova, Ivan Golodnikov, Arina Sleptsova, Larisa Nikankina, Anna Ivanova, et al.

    Background: Type 1 diabetes mellitus (T1DM) is characterised by substantial heterogeneity in clinical manifestations, the rate of β-cell destruction, and diabetes-associated autoantibody (DAA) profiles across individuals of different ethnic backgrounds and ages. We investigated the immunological heterogeneity of T1DM through immunophenotyping of major lymphocyte populations using multiparameter flow cytometry. Results: T1DM associates with distinct immunophenotypes dependent on age, disease stage, DAA profiles, and the presence of Diabetic Ketoacidosis (DKA). Paediatric T1DM (n = 49) shows attenuated innate immunity (fewer NK and MAIT cells) alongside higher T-cell activation. Adult T1DM (n = 55) features remodelling in NK-cell receptor landscape, specifically expanding CD8+, CD38+, CD161+, and NKG2A+ NK-cell subsets. Long-standing T1DM (n = 28) combines higher CD8+ T-cell cytotoxicity with lower NK-cell cytotoxicity. High Autoantibody / Multi-antibody T1DM is marked by fewer CD8+ T cells, B cells, protective NKregs, and MAIT cells, but more CD38+ NK cells. Seronegative / Low Antibody T1DM shows a drop in total NK and NKeff cells, but an expansion of inhibitory, CD56bright, and CD8+ NK subsets. Paediatric DKA is linked to fewer innate-like T cells and more activated T cells. Adult DKA is characterized by drops in various NK cells (CD3-CD56+, CD3-CD8+, NKeff) and specific T cells (CD8+CD161+ and CD161+ double-negative). Conclusions: The immunological heterogeneity identified in patients with T1DM underscores the importance of patient stratification, which may facilitate the discovery of predictive and prognostic cellular biomarkers capable of estimating the rate of progression to clinically manifest T1DM and the risk of an aggressive disease course, respectively.

  • Open Access

    Single-cell immune transcriptomics reveals an inflammatory-inhibitory set-point spectrum in autoimmune diabetes

    by Ivan I. Golodnikov, Elizaveta S. Podshivalova, Vadim I. Chechekhin, Anatoliy V. Zubritskiy, Alina A. Matrosova, Nikita A. Sergeev, Margarita D. Samsonova, Yaroslav V. Dvoryanchikov, Tatiana V. Nikonova, Ekaterina V. Bondarenko, et al.

    Autoimmune diabetes encompasses rapidly progressive type 1 diabetes mellitus (T1D) and indolent latent autoimmune diabetes in adults (LADA), which represent distinct inflammatory set points along a shared autoimmune spectrum. Yet, the immunological mechanisms that determine these divergent inflammatory states remain unresolved. We performed single-cell RNA sequencing with paired T and B cell receptor profiling on over 400,000 PBMCs from patients with LADA, newly diagnosed T1D, and individuals acting as healthy controls. PBMC composition was comparable across cohorts, indicating that qualitative rather than quantitative immune differences underlie disease heterogeneity. In T1D, pan-lineage activation of NF-κB, EGFR, MAPK, and hypoxia pathways, coupled with a TNF-centered communication hub, enhanced MHC signaling, disrupted adhesion, and promoted systemic inflammation. LADA, by contrast, exhibited global suppression of NF-κB/EGFR activity, retention of moderate JAK/STAT tone, reinforced NK cell inhibitory checkpoints via HLA-C–KIR2DL3/3DL1 interaction, and stabilized CD8 + T cell synapses through HLA-C–CD8 binding, collectively restraining effector activation. Single-cell V(D)J analysis revealed multiclonal, patient-unique adaptive repertoires, emphasizing the primacy of signaling context over receptor convergence. These findings define autoimmune diabetes as an inflammatory-inhibitory set-point continuum, positioning the NF-κB/EGFR–JAK/STAT gradient and HLA-C–KIR axis as potential therapeutic targets to preserve residual β cell function.


  • Open Access

    Rare BLK, CEL, KLF11, PDX1, and PAX4 Gene Variants in Russian Patients with Monogenic Diabetes: Clinical and Molecular Characterization

    by Rita I. Khusainova, Ildar R. Minniakhmetov, Dmitry N. Laptev, Mariya P. Koltakova, Roman V. Deev, Bulat I. Yalaev, Yaroslav V. Dvoryanchikov, Elena A. Sechko, Natalia G. Mokrysheva

    Background: Maturity-onset diabetes of the young (MODY) is a heterogeneous group of monogenic diabetes forms that are frequently misclassified as type 1 or type 2 diabetes due to overlapping phenotypic features. The true prevalence of MODY is likely substantially underestimated. As DNA-based diagnostics become increasingly accessible, an expanding number of novel genetic variants are being identified. Objectives: The aim of this study was to characterize the clinical and genetic features of patients carrying rare variants in the BLK, KLF11, PAX4, PDX1, and CEL genes, with attention to population-specific aspects, family history, and treatment outcomes. Methods: Targeted next-generation sequencing (NGS) using a custom-designed panel covering 27 genes implicated in MODY, neonatal diabetes, and related hereditary syndromes was performed on the Illumina NovaSeq 6000 platform (Illumina). Results: We identified 21 variants in five genes associated with rare MODY subtypes among 24 unrelated patients. MODY9 was diagnosed in two unrelated patients of Russian ethnicity harboring an identical heterozygous missense mutation in exon 5 of the PAX4 gene (HG38, chr7:127615049G>A, c.191C>T, p.Thr64Ile), which has not been previously described in patients with diabetes. MODY11 was diagnosed in a patient carrying the c.773-1G>A variant in the BLK gene. A patient with a de novo c.40_41dupGC (p.Val15Glnfs*41) variant in the KLF11 gene was clinically diagnosed with type 1 diabetes. Conclusion: Our findings expand the current understanding of rare MODY subtypes and contribute to the growing body of evidence on the spectrum and frequency of potentially pathogenic variants in BLK, CEL, KLF11, PDX1, and PAX4 genes across ethnically diverse populations worldwide.


  • Open Access

    Genetic Structure of Hereditary Forms of Diabetes Mellitus in Russia

    by Ildar R. Minniakhmetov, Rita I. Khusainova, Dmitry N. Laptev, Bulat I. Yalaev, Yulia S. Karpova, Roman V. Deev, Ramil R. Salakhov, Dmitry D. Panteleev, Kirill V. Smirnov, Galina A. Melnichenko, et al.

    Analyzing the genetic architecture of hereditary forms of diabetes in different populations is a critical step toward optimizing diagnostic and preventive algorithms. This requires consideration of regional and population-specific characteristics, including the spectrum and frequency of pathogenic variants in targeted genes. As part of this study, we used a custom-designed NGS panel to screen for mutations in 28 genes associated with the pathogenesis of hereditary diabetes mellitus in 506 unrelated patients from Russia. The study identified 180 pathogenic or likely pathogenic variants across 13 genes (GCK, HNF1A, HNF1B, HNF4A, ABCC8, INS, INSR, KCNJ11, PAX4, PDX1, ZFP57, BLK, WFS1), representing 46.44% of the analyzed cohort (235 individuals). The glucokinase gene (GCK) had the highest number of identified variants, with 111 variants detected in 161 patients, 20 of which were identified for the first time. In the tissue-specific transcription factor genes HNF1A, HNF4A, and HNF1B, 34 variants were found in 38 patients, including 13 that were previously unreported. Seventeen variants were identified in the ABCC8 gene, which encodes the ATP-binding cassette transporter 8 of subfamily C, each found in a different patient; four of these were novel discoveries. Nine pathogenic or likely pathogenic variants were identified in the insulin gene (INS) and its receptor gene (INSR), including four previously unreported variants. Additionally, we identified 10 previously unreported variants in six other genes among 11 patients. Variants in the genes GCK, HNF1A, HNF1B, HNF4A, ABCC8, INS, and INSR were the main contributors to the genetic pathogenesis of hereditary diabetes mellitus in the Russian cohort. These findings enhance our understanding of the molecular mechanisms underlying the disease and provide a solid basis for future studies aimed at improving diagnostic accuracy and advancing personalized therapeutic strategies. This knowledge provides a foundation for developing region-specific genetic testing algorithms and personalized therapeutic strategies, which are critical for future initiatives in precision medicine.


  • Neonatal diabetes mellitus in a patient with a novel heterozygous mutation in GATA6

    by Elena Sechko, Elizaveta Raykina, Tamara Kuraeva, Dmitry Laptev, Olga Bezlepkina, Valentina Peterkova

    Transient neonatal diabetes mellitus (TNDM) occurs in 50-60% of all cases of neonatal diabetes mellitus (NDM). The most common cause of TNDM (70%) is almost invariably associated with defect in chromosome 6 and mutations in the KCNJ11, ABCC8, INS, NHF1B etc. genes. TNDM is caused by mutations in the GATA6 gene in rare cases. This gene encodes a transcription factor that is important for the development of the hematopoietic, cardiac and gastrointestinal systems. Clinical Case: Proband is a female born at 35 week of gestation with intrauterine growth retardation (weight 1580 g (SDS -2.29), length 40 cm (SDS -2.65)) via cesarean section. The proband was fedded using tube feeding in neonatal period. The proband was diagnosed with hyperglycemia 29.6 mmol/l in the neonatal period, insulin therapy was started. Insulin was stopped in 1 month of life. Normoglycemia was observed. Family history of diabetes was negative. The proband was relapse of diabetes in 3 years old after a respiratory infection. She had polyuria, polydipsia and weight loss. HbA1c 11.5%, glycemia 18.6 mmol/l. Insulin (As part, 0.4 U/kg/day) was started. Fasting C-peptide 0.69 ng/ml, stimulated C-peptide in 120 min - 2.32 ng/ml. Specific islet antibodies (GADA, IA2A, IAA, ZnT8A) were negative. Pancreatic hypoplasia was diagnosed due to ultrasound. Genetic test (NGS 27 genes) was performed, no mutations were detected. Proband had extrapancreatic features: moderate growth retardation (growth SDS -1.95), patent ductus arteriosus, mitral valve prolapse, gallbladder agenesis, umbilical hernia, autoimmune thyroiditis. At the age of 8 years (diabetes duration was 5 years) patient was treated fast acting insulin Aspart, 0.7 U/kg/day. HbA1c 5.2%, fasting C-peptide 0.71 ng/ml, stimulated C-peptide in 120 min – 0.9 ng/ml. Whole-exome sequencing revealed novel pathogenic heterozygous mutation c.1302+4 1302+7del in exon 3 of the GATA6 gene, leading to a deletion of 4 nucleotides. Conclusion: TNDM is rarely caused by mutations in the GATA6 gene. The development of NDM due to mutations in the GATA6 gene is probably associated with pancreatic hypoplasia. Diabetes associated with mutations in the GATA6 gene is progressive. Patients with mutations in the GATA6 gene have extrapancreatic features (congenital heart defects, gallbladder agenesis, umbilical hernia).

  • Open Access

    Features of Slowly Progressive Type 1 Diabetes Mellitus in Overweight Adolescents

    by Elizaveta Romanenkova, Irina Eremina, Lubov Zilberman, Dmitry Laptev, Tamara Kuraeva, Olga Bezlepkina, Valentina Peterkova

    Background: he obesity epidemic has led to an increase in the incidence of type 1 diabetes mellitus (T1DM) on the background of overweight. The combination of T1DM and obesity can lead to an erroneous diagnosis of type 2 diabetes (T2DM). Methods: The study included 35 adolescents with T1DM. Inclusion criteria were obesity at onset, high titer of diabetes-associated autoantibodies, and insulin requirement less than 0.5 U/kg with a diabetes duration of more than 6 months. We assessed the level of HbA1c, fasting level of insulin and c-peptide, and level during the Mixed-Meal Tolerance Test, the immunological status of GADA, IA-2, ZnT8, ICA. Results: The age of onset was 12.7 years [10.6; 14.5], the tanner stage of puberty was 4 [3; 5]. Sex distribution: boys (n = 25) - 71.5%, girls (n = 10) - 28.5%. HbA1c at the time of onset equaled 8,9% [7.4; 10.45]. Ketosis/diabetic ketoacidosis was registered in 47.8%. The duration of the diabetes was 1.7 years at the moment of examination [0.7; 2.9]. The fasting level of C-peptide - 1.37 mμg/ml [1.0.9; 2.19], insulin level (n = 26) - 13.93 uU/ml [9.57; 19.77]. The maximum level of stimulated secretion of C-peptide (n = 21) - 5.13 mμg/ml [3.05; 6.07], of insulin secretion (n = 21) - 58.59 uU/ml [31.02; 79.74]. Higher HOMA of insulin resistance (n = 25) was detected in 72% of the examined patients. In the study of pancreatic autoantibodies, an increase in ICA was detected in 57% (median of titer 1.68 [0.28;11.7]), IA-2 - 67% (192.8 ME/ml [65; 310.1]), GAD - 59% (90.25 ME/ml [32.27; 214.6]), ZnT8 - 82% (350.5 [90.4; 506.05]). The presence of 2 or more autoantibodies is found in 94% of cases. Dyslipidemia was observed in 34.8%, arterial hypertension was identified in 23% of patients. Received therapy: insulin 82%; metformin 0.02%; metformin + insulin 5.7%. Median daily dose per patient was 0.3 U/kg [0.2; 0.5]. Conclusion: T1DM in adolescents with obesity and overweight has a similar clinical picture both with T1DM (insulin dependence, high titer of autoantibodies, ketosis) and T2DM (slow progression of the disease, low insulin requirement, preserved secretion of c-peptide, and insulin for more than 1.5 years). We hypothesize that obesity and insulin resistance may contribute to DM onset at an earlier date, even if a satisfactory function of pancreatic beta-cells is still preserved. Given that the onset of the disease in our group falls on adolescence it seems that pubertal insulin resistance also contributes to the features of the course of the disease. Understanding the role of obesity in the progression of disorders of carbohydrate metabolism will allow postponing the acute manifestation of the disease and initiation of insulin therapy through lifestyle modifications in patients at risk. A long period of preserved insulin secretion opens up the possibility of new personalized therapies.